Clinical Trial Update: European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia [Phase 3]

View source ↗

Summary

A Phase 3 trial of rimonabant in abdominally obese patients with dyslipidemia has been terminated. The update notes the study status but does not provide trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Obesity

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Obesity, Dyslipidemias | Phase 3 | Status: TERMINATED